Heat Biologics intends to conduct public offering of common stock

Bookrunner Joseph Gunnar helps fund clinical trials, working capital

By Devika Patel

Knoxville, Tenn., July 21 – Heat Biologics, Inc. will price a public sale of common stock with a 45-day 15% greenshoe, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Joseph Gunnar & Co., LLC is the bookrunner.

Proceeds will be used for general corporate purposes, including clinical trials and working capital purposes.

The biopharmaceutical company is based in Durham, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.